Index
S&P 500
Market Cap
163.38B
Enterprise Value
185.49B
Income
4.33B
Sales
25.61B
Book/sh
76.23
Cash/sh
8.08
Employees
60000
IPO
Dec 10, 1969
P/E
38.03
Forward P/E
24.94
PEG
2.63
P/S
6.38
P/B
3.05
P/C
28.75
P/FCF
28.53
EV/EBITDA
23.21
EV/Sales
7.24
Quick Ratio
1.29
Current Ratio
1.63
Debt/Eq
0.52
LT Debt/Eq
0.45
Option/Short
Yes / Yes
EPS (ttm)
6.11
EPS next Y
9.31
EPS next Q
2.48
EPS this Y
10.09%
EPS next Y
8.44%
EPS next 5Y
9.48%
EPS past 3/5Y
-19.39% 0.65%
Sales past 3/5Y
-2.67% 1.97%
EPS Y/Y TTM
25.53%
Sales Y/Y TTM
5.52%
EPS Q/Q
37.34%
Sales Q/Q
8.28%
Insider Own
8.98%
Insider Trans
-0.15%
Inst Own
84.00%
Inst Trans
-1.05%
ROA
4.95%
ROE
8.19%
ROIC
5.55%
Gross Margin
58.85%
Oper. Margin
20.94%
Profit Margin
16.91%
SMA20
2.46%
SMA50
6.11%
SMA200
15.47%
Trades
Shs Outstand
703.40M
Shs Float
640.36M
52W High
242.80 -4.35%
52W Low
160.93 44.30%
Volatility
2.54% 3.00%
ATR (14)
6.64
RSI (14)
58.12
Beta
0.78
Rel Volume
0.93
Avg Volume
4.04M
Volume
3,755,006
Perf Week
0.75%
Perf Month
9.67%
Perf Quarter
17.58%
Perf Half Y
32.59%
Perf YTD
1.45%
Perf Year
7.99%
Perf 3Y
25.46%
Perf 5Y
-15.97%
Perf 10Y
235.07%
Prev Close
236.98
Price
232.23
Change %
-2.00%
Analysts 17 incl. previous ratings
Rating Distribution 12 Buy · 5 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Sep 09, 2026 Resumed U UBS
Buy $250 +7.7% Jun 11, 2026 Initiated P Piper Sandler
Neutral $200 -13.9% Jun 03, 2026 Initiated D DZ Bank
Buy $210 -9.6% Jun 02, 2026 Resumed W Wolfe Research
Peer Perform May 26, 2026 Resumed C Citigroup
Buy $230 -1.0% May 15, 2026 Resumed R RBC Capital Mkts
Outperform $200 -13.9% Dec 09, 2025 Initiated G Goldman
Buy $265 +14.1% Dec 02, 2025 Initiated M Morgan Stanley
Overweight $270 +16.3% Oct 08, 2025 Downgrade R Rothschild & Co Redburn
Buy → Neutral $220 -5.3% Jul 11, 2025 Upgrade B Scotiabank
Sector Perform → Sector Outperform $275 +18.4% Apr 10, 2025 Upgrade B Barclays
Equal Weight → Overweight $205 -11.7% Mar 21, 2025 Upgrade G Goldman
Neutral → Buy $260 +12.0% Mar 14, 2025 Upgrade S Stifel
Hold → Buy $260 +12.0% Feb 03, 2025 Downgrade R Raymond James
Outperform → Mkt Perform Dec 23, 2024 Initiated B Scotiabank
Sector Perform Dec 19, 2024 Initiated G Guggenheim
Buy $275 +18.4% Dec 13, 2024 Upgrade B BofA Securities
Neutral → Buy $290 +24.9% Oct 31, 2024 Upgrade W Wolfe Research
Peer Perform → Outperform $285 +22.7% Oct 01, 2024 Initiated S Stephens
Overweight $315 +35.6% Aug 28, 2024 Initiated W Wells Fargo
Equal Weight $280 +20.6%
Show Previous Ratings
Oct-28-26 03:08PM
Oct-21-26 04:59PM
04:30PM
09:53AM
06:41AM
06:09AM
Loading…
06:09AM
06:00AM
04:43AM
03:37AM
Oct-19-26 03:20PM
07:39AM
Oct-14-26 06:57AM
02:00AM
Oct-12-26 04:25PM
Oct-07-26 03:05PM
10:03AM
Loading…
10:03AM
10:00AM
09:32AM
07:40AM
07:00AM
Oct-01-26 04:30PM
07:00AM
Sep-29-26 06:40AM
Sep-28-26 02:45PM
Sep-22-26 04:15PM
Sep-15-26 09:19PM
04:15PM
Sep-08-26 03:37PM
Sep-01-26 06:44AM
Aug-24-26 10:26AM
02:35PM
Loading…
Aug-18-26 02:35PM
Aug-10-26 02:00PM
Aug-04-26 06:56AM
Aug-03-26 04:15PM
Jul-30-26 02:29PM
Jul-24-26 08:25AM
08:23AM
01:30AM
Jul-23-26 04:30PM
Jul-22-26 02:12PM
09:11AM
05:06AM
Jul-21-26 03:00PM
10:29AM
07:16AM
06:49AM
06:31AM
06:10AM
06:00AM
04:09AM
03:38AM
Jul-20-26 10:46AM
Jul-17-26 06:56PM
08:17AM
Jul-03-26 12:26PM
Jun-29-26 08:30AM
Jun-26-26 11:51AM
Jun-24-26 08:05AM
02:18AM
Jun-22-26 04:21PM
04:15PM
Jun-17-26 07:00AM
Jun-16-26 04:57PM
Jun-11-26 09:38AM
03:21AM
Jun-10-26 08:55AM
Jun-08-26 06:42PM
06:09PM
Jun-03-26 08:25AM
May-22-26 08:00AM
May-15-26 04:55AM
01:00AM
May-06-26 04:15PM
May-05-26 04:30PM
May-04-26 05:53PM
09:00AM
Apr-30-26 10:05AM
Apr-29-26 10:30AM
Apr-22-26 07:15PM
03:01AM
Apr-21-26 06:43AM
06:10AM
06:00AM
04:38AM
03:45AM
Apr-17-26 07:16PM
Apr-13-26 03:01AM
Apr-09-26 06:50PM
Mar-27-26 09:46AM
Mar-20-26 04:15PM
Mar-12-26 03:47PM
Feb-27-26 11:30AM
Feb-26-26 11:53PM
Feb-25-26 01:46AM
Feb-24-26 02:31PM
08:33AM
Feb-23-26 10:37AM
Feb-21-26 04:30AM
Feb-20-26 03:49PM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bouda Christopher VP, Chief Accounting Officer Oct 28 '26 Option Exercise 70.74 7,598 537,483 13,452 Oct 29 05:00 PM Bouda Christopher VP, Chief Accounting Officer Oct 28 '26 Sale 234.56 7,598 1,782,157 9,107 Oct 29 05:00 PM McGrew Matthew Executive Vice President Oct 28 '26 Option Exercise 76.47 15,603 1,193,161 28,277 Oct 29 05:00 PM McGrew Matthew Executive Vice President Oct 28 '26 Sale 235.74 29,754 7,014,244 12,674 Oct 29 05:00 PM McGrew Matthew Officer Oct 28 '26 Proposed Sale 235.74 29,754 7,014,244 Oct 28 12:27 PM Blair Rainer President & CEO Aug 21 '26 Sale 218.63 58,255 12,736,095 0 Aug 24 05:00 PM Rainer M. Blair Officer Aug 21 '26 Proposed Sale 218.85 58,255 12,749,107 Aug 21 04:46 PM FILLER LINDA Director Jul 15 '26 Option Exercise 71.88 3,298 237,060 28,010 Jul 16 05:00 PM Zerhouni Elias A. Director Jul 15 '26 Option Exercise 71.88 3,298 237,060 46,484 Jul 16 05:00 PM SCHWIETERS JOHN T Former Director Jul 14 '26 Proposed Sale 199.59 3,298 658,254 Jul 14 11:15 AM SPOON ALAN G Director May 01 '26 Option Exercise 71.88 3,298 237,060 125,452 May 04 05:00 PM SPOON ALAN G Director May 01 '26 Sale 174.67 1,358 237,207 124,094 May 04 05:00 PM SPOON ALAN G Director May 01 '26 Proposed Sale 174.67 1,358 237,207 May 01 03:05 PM Milosevich Gregory M Executive Vice President Feb 19 '26 Option Exercise 58.59 1,320 77,339 6,419 Feb 20 05:00 PM Milosevich Gregory M Executive Vice President Feb 19 '26 Sale 208.01 1,320 274,575 5,099 Feb 20 05:00 PM Milosevich Gregory M Officer Feb 19 '26 Proposed Sale 208.01 1,320 274,575 Feb 19 01:07 PM RALES MITCHELL P Chairman of Exec. Committee Nov 25 '25 Sale 230.38 40,625 9,359,067 850,000 Nov 26 04:30 PM The Mitchell P. Rales Family T See Remarks Nov 25 '25 Proposed Sale 226.98 40,625 9,221,063 Nov 25 05:23 PM Glenstone Foundation See Remarks Nov 25 '25 Proposed Sale 226.98 146,957 33,356,300 Nov 25 05:22 PM List Teri Director Nov 18 '25 Option Exercise 71.88 3,298 237,060 24,060 Nov 19 05:00 PM List Teri Director Nov 18 '25 Sale 226.50 3,298 746,997 20,762 Nov 19 05:00 PM List Teri Director Nov 18 '25 Proposed Sale 226.50 3,298 746,997 Nov 18 03:32 PM McGrew Matthew EVP & Chief Financial Officer Nov 11 '25 Option Exercise 62.85 16,172 1,016,410 36,234 Nov 13 05:00 PM McGrew Matthew EVP & Chief Financial Officer Nov 11 '25 Sale 214.62 16,172 3,470,831 20,062 Nov 13 05:00 PM Ellis Brian W Senior Vice President - GC Nov 12 '25 Option Exercise 58.59 21,776 1,275,856 29,220 Nov 13 05:00 PM Ellis Brian W Senior Vice President - GC Nov 12 '25 Sale 219.23 21,776 4,773,863 14,553 Nov 13 05:00 PM RALES MITCHELL P Chairman of Exec. Committee Nov 12 '25 Sale 218.69 437,000 95,566,167 553,228 Nov 13 04:30 PM Couchara Georgeann SVP, Human Resources Nov 10 '25 Option Exercise 88.24 4,176 368,490 7,799 Nov 12 05:00 PM Couchara Georgeann SVP, Human Resources Nov 10 '25 Sale 210.42 5,174 1,088,704 2,625 Nov 12 05:00 PM Mitchell P. Rales Dir; Chmn. of Exec. Comm. Nov 12 '25 Proposed Sale 209.94 437,000 91,743,780 Nov 12 04:30 PM Ellis Brian W Officer Nov 12 '25 Proposed Sale 219.23 21,776 4,773,864 Nov 12 02:35 PM McGrew Matthew Officer Nov 11 '25 Proposed Sale 214.62 16,172 3,470,831 Nov 12 08:56 AM Couchara Georgeann Officer Nov 10 '25 Proposed Sale 210.42 5,174 1,088,704 Nov 10 02:46 PM
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
Co-Founder & Chairman Mr. Steven M. Rales
President Ms. Julie Sawyer Montgomery
Co-Founder & Director Mr. Mitchell P. Rales
Senior VP & Chief Science Officer Dr. Jose-Carlos Gutierrez-Ramos Ph.D.
Executive Vice President Mr. Matthew R. McGrew